(8alpha,9R)-6'-甲氧基辛可宁-9-醇 | 549-50-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 金鸡纳生物碱
• 中文名称: (8alpha,9R)-6'-甲氧基辛可宁-9-醇
• 英文名称: Quinine hydriodide
• 英文别名: (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydroiodide
• CAS: 549-50-8
• 化学式: C20H25IN2O2
• 分子量: 452.3
• InChiKey: OFBSOLQELKDLEH-DSXUQNDKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.79
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  45.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1(b)

文献信息

• Sulfamoyl sulfonate prodrugs
  申请人：Wyrwa Ralf

  公开号：US20070135375A1

  公开（公告）日：2007-06-14

  The invention relates to sulfamoyl sulfonate prodrugs of general formula I, a process for their production, pharmaceutical compositions that contain these compounds, and their use for the production of orally available pharmaceutical agents. The compounds according to the invention bind to carbonic anhydrases and inhibit these enzymes.

  本发明涉及一类通式I的磺酰胺磺酸酯前药，其生产方法，包含这些化合物的药物组合物，以及它们用于生产口服可用药物剂的应用。根据发明的化合物能与碳酸酐酶结合并抑制这些酶。
• Heteroaromatic sulphonamide prodrugs
  申请人：Wyrwa Ralf

  公开号：US20070135399A1

  公开（公告）日：2007-06-14

  The invention relates to sulphonamide prodrugs of the general formula I, having a heteroaromatic linker, to a process for their preparation, to pharmaceutical compositions comprising these compounds and to their use for the production of orally available medicaments. The compounds according to the invention bind to carboanhydrases and inhibit these enzymes.

  该发明涉及一般式I的磺胺前药，具有杂芳链，以及它们的制备方法，包含这些化合物的药物组合物，以及它们用于制备口服药物的用途。根据该发明的化合物结合到碳酸酐酶并抑制这些酶。
• Compounds with sulphonamide group and pharmaceutical compositions containing these compounds
  申请人：——

  公开号：US20040014781A1

  公开（公告）日：2004-01-22

  The invention relates to compounds which, acting as a prodrug and/or support, enable an active agent to be taken up by the erythrocytes and/or an active agent to bind to the erythrocytes. The uptake of these compounds by and/or the binding thereof to the erythrocytes is made possible by a group of formula —SO2NR1R2, wherein R1 and R2, independently of each other, mean a hydrogen atom, an acyl group, an alkyl group, a cycloalkyl group, an aryl group, a cyano group or a hydroxy group. The inventive prodrugs enable active agents such as endogenic substances, natural substances and synthetic substances with therapeutically useful properties which have a high “first path” effect, to be administered orally effectively or significantly improve the oral activity thereof.

  本发明涉及的化合物作为原药和/或支持物，可使活性剂被红细胞吸收和/或使活性剂与红细胞结合。这些化合物被红细胞吸收和/或与红细胞结合是通过式 -SO2NR1R2 的基团实现的，其中 R1 和 R2 相互独立地表示氢原子、酰基、烷基、环烷基、芳基、氰基或羟基。本发明的原药可以有效地口服具有高 "第一路径 "效应的活性剂，如内源性物质、天然物质和具有治疗作用的合成物质，或显著提高其口服活性。
• METHODS AND COMPOSITIONS FOR LOWERING INTRAOCULAR PRESSURE
  申请人：VIDE PHARMACEUTICALS

  公开号：EP0724443A1

  公开（公告）日：1996-08-07
• EP0724443A4
  申请人：——

  公开号：EP0724443A4

  公开（公告）日：1997-09-10